cancer

Not only will the needs of each and every client who needs a protection policy differ, but advisers also have to factor in the different underwriting processes of providers...

The Cancer Drugs Fund has led to a ‘devastating divide' in access to treatment between England and other home nations, according to a cancer charity.

The National Institute for Health and Clinical Excellence (NICE) has rejected another cancer drug for the NHS due to its cost.

The NHS exceeded all seven of its targets for cancer diagnosis and treatment during the last year, new data has revealed.

Cancer survivors are at greater risk of recurrence because they are not physically active enough, Macmillan Cancer Support has said.

Bupa has launched a new private medical insurance (PMI) product on to the direct market.

Cancer patients could lose up to £94 a week in benefits as the government cuts costs, Macmillan Cancer Support has warned.

The National Institute for Health Clinical Excellence (Nice) has provisionally rejected three commonly used leukaemia drugs for being too expensive compared to the benefit they bring.

The National Institute for Health and Clinical Excellence (Nice) has taken responsibility for helping the NHS to optimise its use of medicines with its absorption of the National Prescribing Centre (NPC).

Bupa has announced it will no longer sell corporate private medical insurance (PMI) schemes which feature overall cost or time limits for cancer treatment.